



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.biodiem.com

Announcement

Australian Life Science Investment Showcase Presentation in San Francisco

Melbourne, 23 June 2014:

BioDiem's CEO, Julie Phillips presented at the Australian Life Science Investment Showcase held in San Francisco on Friday 20 June 2014. The event was timed to precede the enormous BIO 2014 International Convention to be held in San Diego this week. The Showcase event was designed to spotlight and celebrate the achievements and opportunities in the Australian biotech sector. The BioDiem presentation focused on BioDiem's BDM-I and the opportunity presented by the antimicrobial for collaboration and investment.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email jphillips@biodiem.com